Company ReputationThe company boasts a solid reputation among customers, known for its therapeutic expertise, high quality, global footprint, and regulatory experience.
Financial PerformanceCharles River delivered a solid EPS beat ($2.80 vs street estimates of $2.40) on lower opex on modest top line leverage.
Growth PotentialNoveprim and other M&A should aid 2H results, at higher-than-average margin, while services continue to shine.